secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tenaya Therapeutics, Inc. (TNYA)
CIK:        0001858848
Form:       8-K
Filed at:   2026-05-06T23:59:59+00:00
Accession:  0001193125-26-208975
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tenaya reports Q1 net loss $19.3M, cash $80.9M; Alnylam deal; TN-201/401 data expected Q2 2026
--------------------------------------------------------------------------------

- Net loss $19.3M ($0.09/share) vs $26.9M ($0.24/share) in Q1 2025; cash $80.9M as of Mar 31, 2026.
- Alnylam collaboration: $10M upfront, up to $1.1B milestones; cash runway into H2 2027 inclusive of upfront.
- TN-201 (HCM gene therapy): interim Cohort 2 data and Cohort 1 update expected Q2 2026; enrollment resumed after protocol amendments.
- TN-401 (ARVC gene therapy): one-year Cohort 1 and initial Cohort 2 data to be presented at ASGCT May 15, 2026.
- TN-301 (HDAC6i) granted Rare Pediatric and Orphan Drug Designation for DMD; preclinical data showed improved grip strength.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1858848/000119312526208975/0001193125-26-208975-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1858848/000119312526208975/tnya-20260506.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-208975

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer